Sarepta Therapeutics (SRPT) To Report Earnings Tomorrow: Here Is What To Expect

Biotech company Sarepta Therapeutics (NASDAQ:SRPT) will be reporting results tomorrow after the bell. Here’s what you need to know.

Sarepta Therapeutics beat analysts’ revenue expectations by 15.4% last quarter, reporting revenues of $467.2 million, up 40.8% year on year. It was an incredible quarter for the company, with an impressive beat of analysts’ EPS estimates.

Is Sarepta Therapeutics a buy or sell going into earnings? Read our full analysis here, it’s free.

This quarter, analysts are expecting Sarepta Therapeutics’s revenue to grow 59.1% year on year to $631.3 million, improving from the 53.5% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $2.06 per share.

Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Sarepta Therapeutics has missed Wall Street’s revenue estimates three times over the last two years.

Looking at Sarepta Therapeutics’s peers in the therapeutics segment, some have already reported their Q4 results, giving us a hint as to what we can expect. BioMarin Pharmaceutical delivered year-on-year revenue growth of 15.6%, beating analysts’ expectations by 4.8%, and Myriad Genetics reported revenues up 7.1%, falling short of estimates by 0.6%. BioMarin Pharmaceutical traded up 4.6% following the results.

Read our full analysis of BioMarin Pharmaceutical’s results here and Myriad Genetics’s results here.

Stocks, especially growth stocks where cash flows further in the future are more important to the story, had a good 2024. An economic soft landing (so far), the start of the Fed's rate cutting campaign, and the election of Donald Trump were positives for the market, and while some of the therapeutics stocks have shown solid performance, the group has generally underpeformed, with share prices down 5.4% on average over the last month. Sarepta Therapeutics is down 9.1% during the same time and is heading into earnings with an average analyst price target of $181.78 (compared to the current share price of $106.20).

Unless you’ve been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story.